No price history available.
Key financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | ¥m | 339,607 | 337,406 | 375,720 | 399,921 | 414,265 | 422,032 | 421,563 | N/A | N/A |
| Operating profit | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | ¥m | 13,774 | 4,202 | 12,865 | -655 | 2,455 | 2,003 | 11,174 | N/A | N/A |
| EPS reported | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | ¥m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | ¥ | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in JPY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | 2027E | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Value | ||||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | ||||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | ||||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | ||||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Established in 1882 and headquartered in Osaka, Japan, Toyobo Co., Ltd. is a global enterprise delivering a diverse range of products. The company specializes in the manufacturing of films and advanced polymers, industrial components, healthcare solutions, and various textile goods. Its films and functional polymers division produces industrial PET films for applications such as liquid crystal displays and optics, in addition to synthetic papers. It also supplies a variety of packaging films, including PET, polyolefin, and nylon options for food products, along with heat-shrink PET films. The company's portfolio of functional polymers features engineering plastics, industrial adhesives, specialized coatings, photosensitive printing plates, acrylate polymers, and electronic materials. This segment further encompasses rubber and coat processing, as well as pharmaceutical intermediates. Within its industrial materials segment, Toyobo develops functional fibers for airbag construction, polyethylene fibers, and PBO fibers. It also creates functional filters for automotive and indoor environments, materials for anti-pollution solvent adsorption, and fiber components utilized in vehicle parts. In the healthcare sector, the company provides a comprehensive selection of bio-products, which includes enzymes for diagnostic purposes, diagnostic systems, and research reagents. Its contributions also extend to artificial kidney hollow fibers, anti-clotting substances, and seawater desalination modules. For textiles, Toyobo supplies functional fabrics suitable for sports clothing, undergarments, and uniforms, alongside synthetic filaments. The company markets apparel under its Munsingwear brand, acrylic fibers under Exlan, and acrylate fibers under the eks brand, while also engaging in general textile product commerce. Beyond these offerings, Toyobo serves as a contract manufacturer for injectable pharmaceuticals.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Established in 1882 and headquartered in Osaka, Japan, Toyobo Co., Ltd. is a global enterprise delivering a diverse range of products. The company specializes in the manufacturing of films and advanced polymers, industrial components, healthcare solutions, and various textile goods. Its films and functional polymers division produces industrial PET films for applications such as liquid crystal displays and optics, in addition to synthetic papers. It also supplies a variety of packaging films, including PET, polyolefin, and nylon options for food products, along with heat-shrink PET films. The company's portfolio of functional polymers features engineering plastics, industrial adhesives, specialized coatings, photosensitive printing plates, acrylate polymers, and electronic materials. This segment further encompasses rubber and coat processing, as well as pharmaceutical intermediates. Within its industrial materials segment, Toyobo develops functional fibers for airbag construction, polyethylene fibers, and PBO fibers. It also creates functional filters for automotive and indoor environments, materials for anti-pollution solvent adsorption, and fiber components utilized in vehicle parts. In the healthcare sector, the company provides a comprehensive selection of bio-products, which includes enzymes for diagnostic purposes, diagnostic systems, and research reagents. Its contributions also extend to artificial kidney hollow fibers, anti-clotting substances, and seawater desalination modules. For textiles, Toyobo supplies functional fabrics suitable for sports clothing, undergarments, and uniforms, alongside synthetic filaments. The company markets apparel under its Munsingwear brand, acrylic fibers under Exlan, and acrylate fibers under the eks brand, while also engaging in general textile product commerce. Beyond these offerings, Toyobo serves as a contract manufacturer for injectable pharmaceuticals.